AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Learn the 7 vital bladder cancer warning signs that require immediate medical attention, including subtle early symptoms many ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

This study explores the relationship between gallstones, cholecystectomy, and cancer risk through both observational and ...

ABOUT 55,000 new prostate cancer cases are recorded every year in the UK. Bladder cancer is less common, with around 10,500 ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

Bladder cancer spreads at different speeds depending on the type of bladder cancer you have. Urothelial bladder cancer is slow to spread, while other types are much faster. Urothelial bladder ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.